Jim Simons
MREO icon

Jim Simons’s Mereo BioPharma MREO Stock Holding History

Jim Simons’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Buy
52,100
+3,700
+8% +$1.11K ﹤0.01% 3105
2026
Q1 		$16K Sell
48,400
-145,971
-75% -$62.6K ﹤0.01% 3182
2025
Q4 		$81K Sell
194,371
-396,500
-67% -$755K ﹤0.01% 3034
2025
Q3 		$1.22M Sell
590,871
-889,600
-60% -$1.64M ﹤0.01% 2384
2025
Q2 		$4.01M Buy
1,480,471
+130,000
+10% +$314K 0.01% 1659
2025
Q1 		$3.04M Buy
1,350,471
+161,000
+14% +$455K ﹤0.01% 1732
2024
Q4 		$4.16M Sell
1,189,471
-115,900
-9% -$455K 0.01% 1565
2024
Q3 		$5.37M Sell
1,305,371
-456,632
-26% -$1.89M 0.01% 1404
2024
Q2 		$6.34M Buy
1,762,003
+89,694
+5% +$291K 0.01% 1165
2024
Q1 		$5.52M Sell
1,672,309
-125,700
-7% -$426K 0.01% 1355
2023
Q4 		$4.15M Buy
1,798,009
+70,439
+4% +$135K 0.01% 1468
2023
Q3 		$2.23M Sell
1,727,570
-51,202
-3% -$67.9K ﹤0.01% 1795
2023
Q2 		$2.35M Buy
1,778,772
+862,863
+94% +$1M ﹤0.01% 1891
2023
Q1 		$647K Sell
915,909
-341,460
-27% -$307K ﹤0.01% 2734
2022
Q4 		$943K Buy
1,257,369
+23,755
+2% +$19.5K ﹤0.01% 2570
2022
Q3 		$1.06M Buy
1,233,614
+624,705
+103% +$764K ﹤0.01% 2460
2022
Q2 		$682K Buy
608,909
+325,109
+115% +$252K ﹤0.01% 2963
2022
Q1 		$318K Buy
283,800
+63,200
+29% +$81.7K ﹤0.01% 3446
2021
Q4 		$353K Sell
220,600
-178,300
-45% -$357K ﹤0.01% 3267
2021
Q3 		$965K Buy
398,900
+113,800
+40% +$301K ﹤0.01% 2573
2021
Q2 		$904K Buy
285,100
+17,900
+7% +$60.1K ﹤0.01% 2717
2021
Q1 		$900K Sell
267,200
-92,000
-26% -$325K ﹤0.01% 2656
2020
Q4 		$1.29M Buy
359,200
+338,000
+1,594% +$847K ﹤0.01% 2374
2020
Q3 		$56K Sell
21,200
-29,200
-58% -$85.3K ﹤0.01% 3265
2020
Q2 		$154K Buy
+50,400
New +$88.9K ﹤0.01% 3207
2020
Q1 		– Sell
-126,323
Closed -$414K – 3664
2019
Q4 		$414K Sell
126,323
-39,800
-24% -$102K ﹤0.01% 2964
2019
Q3 		$495K Sell
166,123
-29,800
-15% -$90.1K ﹤0.01% 2872
2019
Q2 		$494K Buy
+195,923
New +$857K ﹤0.01% 3005

Other funds holding MREO

Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Defilade Capital Management
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Jim Simons's MREO Position: Q2 2026 in Review

Jim Simons increased its Mereo BioPharma (MREO) stake by 7.6% in Q2 2026, buying an estimated $1.11K and bringing the position to 52,100 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3105.

Jim Simons first reported a position in MREO in Q2 2019 and has held it in 28 quarters since. The position peaked at $6.34M in Q2 2024. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • Jim Simons held 52,100 shares of Mereo BioPharma worth $16.6K as of Q2 2026.
  • Jim Simons bought 3,700 Mereo BioPharma shares in Q2 2026, an estimated $1.11K.
  • Mereo BioPharma made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #3105 holding.
  • Jim Simons first reported a position in Mereo BioPharma in Q2 2019 and has held it in 28 quarters since.
  • Jim Simons's Mereo BioPharma position peaked at $6.34M in Q2 2024.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.